



## **FOR IMMEDIATE RELEASE**

Guardion Health Sciences, Inc.  
15150 Avenue of Science, Ste. 200  
San Diego, CA 92128  
Ph 858.605.9055; Fax 858.630.5543  
[www.guardionhealth.com](http://www.guardionhealth.com)

---

# **Guardion Health Sciences, Inc. Receives Official Trademark Registrations in China**

**Guardion’s Lumega-Z product and MapcatSF device are key components of its two-pronged evidence-based protocol for the treatment of a depleted macular protective pigment, a known risk factor for age-related macular degeneration**

**San Diego, CA – April 30, 2019** – Guardion Health Sciences, Inc. (“Guardion” or the “Company”) (Nasdaq: GHSI), an ocular health sciences and technologies company that develops, formulates and distributes condition-specific medical foods and testing technologies supported by evidence-based protocols, today announced that it was recently notified by the State Intellectual Property Office of the People’s Republic of China (“China”) that it has been granted trademark registrations in China for its proprietary medical food, Lumega-Z (Registration No. 27151643), and for its proprietary medical device, the MapcatSF (Registration No. 27151644).

The trademark registration for Lumega-Z is effective from November 7, 2018 to November 6, 2028, and the trademark registration for the MapcatSF is effective from October 28, 2018 to October 27, 2028. The granting of these trademark registrations in China is an important step in the Company’s efforts to introduce the Company’s proprietary products and services to the Chinese marketplace.

Michael Favish, Guardion’s President and Chief Executive Officer, commenting on the granting of the trademark registrations in China, stated “We believe that China, with its large and growing aging population, represents a substantial market opportunity for us, and the establishment of intellectual property rights for our products and services in China will help Guardion in its efforts to gain market acceptance for Lumega-Z and the MapcatSF. This development is an important first step in what are expected to be further investments by Guardion in China as we introduce our products and services to this important and dynamic market.”

Information and risk factors with respect to Guardion and its business, including its ability to successfully develop and commercialize its proprietary products and technologies, may be obtained in the Company’s filings with the Securities and Exchange Commission (“SEC”) at [www.sec.gov](http://www.sec.gov).

### **About Guardion Health Sciences, Inc.**

Guardion is an ocular health sciences company that develops, formulates and distributes condition-specific medical foods supported by evidence-based protocols, with an initial medical food product, Lumega-Z, that addresses a depleted macular protective pigment, a known risk factor for age-

related macular degeneration (“AMD”) and a significant component of functional vision performance. Guardion Health Sciences, Inc. has also developed a proprietary medical device, the MapcatSF®, which accurately measures the macular pigment density, therefore providing the only two-pronged evidence-based protocol for the treatment of a depleted macular protective pigment.

### **About VectorVision®**

VectorVision®, operating through a wholly-owned subsidiary of the Company, specializes in the standardization of contrast sensitivity, glare sensitivity, low contrast acuity, and ETDRS acuity vision testing. Its patented standardization system provides the practitioner or researcher the ability to delineate very small changes in visual capability, either as compared to the population or from visit to visit. VectorVision®’s CSV-1000 device is considered the standard of care for clinical trials.

### **Forward-Looking Statement Disclaimer**

*With the exception of the historical information contained in this news release, the matters described herein may contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These statements involve unknown risks and uncertainties that may individually or materially impact the matters discussed herein for a variety of reasons that are outside the control of the Company, including, but not limited to, the Company’s ability to raise sufficient financing to implement its business plan and its ability to successfully develop and commercialize its proprietary products and technologies. Readers are cautioned not to place undue reliance on these forward-looking statements, as actual results could differ materially from those described in the forward-looking statements contained herein. Readers are urged to read the risk factors set forth in the Company’s filings with the SEC, which are available at the SEC’s website ([www.sec.gov](http://www.sec.gov)). The Company disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.*

*Company Contact:*

*Michael Favish*

*Chief Executive Officer*

*Telephone: (858) 605-9055 x 201*

*E-mail: [mfavish@guardionhealth.com](mailto:mfavish@guardionhealth.com)*

*Investor Relations Contact:*

*Matthew Abenante*

*Porter, LeVay & Rose, Inc.*

*Telephone: (212) 564-4700*

*E-mail: [matthew@plrinvest.com](mailto:matthew@plrinvest.com)*